India’s Union Health Ministry proposed amendments to the Drugs Rules, 1945, to allow immediate suspension of pharmaceutical manufacturing licences when medicines fail specified quality tests. The draft was notified on November 4, 2026.
Proposed licensing action
Under the proposal, a central or state drug licensing authority could suspend a licence if a government analyst finds deficiencies in any of five parameters: assay, dissolution, related substances, impurities or sterility. Suspension would continue until the manufacturer identifies the root cause and implements corrective and preventive actions verified by the authority. Current procedures include a show-cause notice before suspension or cancellation, potentially allowing Not of Standard Quality (NSQ) medicines to remain in circulation.
Reporting and public consultation
The draft, dated October 28, would require reports on substandard drugs to be sent to the Drug Controller General of India, the relevant state or Union Territory licensing authority, and the manufacturer and marketer. Stakeholders and the public were invited to submit objections and suggestions within 30 days. The proposal follows scrutiny of Indian pharmaceutical standards after locally made cough syrups were linked to child deaths in The Gambia, Uzbekistan and India during 2022–2023.
Important Facts for Exams
- Drug-quality standards: The Drugs Controller General of India lays down standards for the manufacture, sale, import and distribution of drugs in India.
- Reference standards: The Drugs Controller General of India is responsible for preparing and maintaining national reference standards, which support consistent drug-quality assessment.
- Manufacturing compliance schedule: Schedule M of the Drugs Rules sets Good Manufacturing Practices and requirements for premises, plant, equipment, production and quality control in pharmaceutical manufacture.
- Analyst-report evidentiary status: Section 25 of the Drugs and Cosmetics Act makes a Government Analyst’s report evidence of its stated facts, while providing a statutory route to contest it.
